UniPhi

Aerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023

Retrieved on: 
Thursday, October 5, 2023
Inhalation, IND, UniPhi, Pharmaceutical industry

DURHAM, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary disease, today announced that pharmacokinetic modeling data for AER-901, a proprietary liquid formulation of imatinib for inhalation that is administered by a breath-activated, high-performance, handheld, smart nebulizer, will be presented at the upcoming CHEST 2023 conference.

Key Points: 
  • DURHAM, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary disease, today announced that pharmacokinetic modeling data for AER-901, a proprietary liquid formulation of imatinib for inhalation that is administered by a breath-activated, high-performance, handheld, smart nebulizer, will be presented at the upcoming CHEST 2023 conference.
  • CHEST 2023 is being held October 8-11, 2023, at the Hawai’i Convention Center in Honolulu, Hawaii.
  • The pharmacokinetic modeling data, which will be presented by Dr. Gary Burgess, Chief Medical Officer of Aerami, extend pharmacokinetic findings from the completed Phase 1 clinical trial of AER-901 in healthy volunteers (NCT04903730) to support dose and dosing regimen selection for the planned “uniPHied” Phase 2 platform trial in PH-ILD and PAH.
  • In Q3 2023 the AER-901 investigational new drug (IND) application with the United States Food and Drug Administration was updated for Phase 2 clinical development; data from the AER-901 Phase 1 clinical trial and the uniPHied clinical trial protocol were included among the updates.

Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress

Retrieved on: 
Tuesday, September 12, 2023
Inhalation, Mico, PAH, Lung, ERS, Congress, HIV disease progression rates, Novartis, European Respiratory Society, UniPhi, Orthostatic hypertension, Pulmonary hypertension, Second International Congress on Education of the Deaf, Safety, Disease, Pharmaceutical industry

The ERS International Congress is being held September 9-13, 2023, at the MiCo convention center in Milan, Italy.

Key Points: 
  • The ERS International Congress is being held September 9-13, 2023, at the MiCo convention center in Milan, Italy.
  • The oral presentation and e-poster are available through the conference portal and will be posted to the Aerami website following the meeting.
  • In a Phase 3 clinical trial sponsored by Novartis, oral imatinib demonstrated substantial efficacy when added to 2 or 3 background standard-of-care medications for PAH.
  • Clinical data presented at the 2023 ERS International Congress include safety, tolerability, and pharmacokinetic results from the AER-901 Phase 1 trial.

Grupo Antolin and Uniphy Partner to Develop Advanced Smart Surfaces for Next Generation In-Car User-Interfaces

Retrieved on: 
Wednesday, March 16, 2022
Program, Solution, Antolin, Technology, Glass cockpit, Original equipment manufacturer, Electronic Systems, Somatosensory system, Grupo Antolin, Mark (given name), HMI, Algorithm, HMIS, User interface, 3D, Electronics, Lighting, Crowdsourcing as Human-Machine Translation, 3D printing, Industrial design, UniPhi

Thanks to this collaboration, Grupo Antolin will combine its advanced decorative and lighting technologies with Uniphy's revolutionary Canvyasmart-surface solutions to enable new highly functional 3D touch-control surfaces that are beautiful, intuitive, robust, safe, and economic.

Key Points: 
  • Thanks to this collaboration, Grupo Antolin will combine its advanced decorative and lighting technologies with Uniphy's revolutionary Canvyasmart-surface solutions to enable new highly functional 3D touch-control surfaces that are beautiful, intuitive, robust, safe, and economic.
  • Together we can produce unique smart 3D surfaces that can be seamlessly integrated into all interior parts of next generation vehicles.
  • "Antolin & Uniphy have the combined expertise to make decorative trim immersivity functional in a highly efficient and cost-effective way.
  • Grupo Antolin offers high added value products via four Business Units: Overheads, Cockpits & Doors, Lighting & HMI, and Electronic Systems.

Uniphy Limited and Hyundai Motor Group to Collaborate on Next Generation Smart Human-­Machine Interfaces (HMls) for Automotive

Retrieved on: 
Wednesday, March 2, 2022
Hyundai, 3D, UAM, EV, Hyundai Motor Company, Robotics, Solution, Urban air mobility, CEO, Algorithm, HML, Hyundai Motor Group, Voice user interface, Technology, HMIS, European, HMI, Somatosensory system, Humanity, Motor vehicle, 3D printing, Mobile phone, UniPhi

Hyundai Motor European Technical Center GmbH (HMETC) is the European R&D center of Hyundai Motor Group.

Key Points: 
  • Hyundai Motor European Technical Center GmbH (HMETC) is the European R&D center of Hyundai Motor Group.
  • HMETC is a world-class Automotive R&D center which continuously monitors innovative technologies and creates original concepts, which may ultimately find their way into production vehicles.
  • "We are delighted and honored to collaborate with Hyundai Motor Group- an automotive world leader with a stated and demonstrated commitment to relentless and responsible innovation.
  • Based on the brand vision 'Progress for Humanity,' Hyundai Motor is accelerating its transformation into a Smart Mobility Solution Provider.